ABSTRACT
poorly understood and consequent advice on prevention is not possible [3] . Therefore, the management of prostate cancer focuses on treating the disease, and the hormone dependence of prostate cancer has been recognized for decades [4] . As a consequence, testosterone suppression has been the standard palliative treatment in men with advanced prostate cancer for many years. Orchiectomy is a simple, low-cost surgical procedure that effectively and quickly achieves castration, but because it is irreversible and does not allow intermittent treatment, it has become less popular than hormonal therapies among patients.
The selection of appropriate treatment is mainly dependent on the stage of disease and the risk of progression. Prostate cancer is generally described as localized, locally advanced (when the tumor has extended beyond the capsule of the prostate) and metastatic disease, and is classified using the Tumor-lymph Nodes-Metastasis (TNM) system [5] . Patients are also categorized into low, high, or intermediate risk of progression according to clinical stage, Gleason score, and prostate-specific antigen (PSA) level [6] , and this will continue with the adoption of the recent International Society of Urological Pathology (ISUP) modified Gleason grading patterns [7] . However, a recent assessment of a large cohort found that while high levels of PSA ([100 ng/ml) at diagnosis were associated with a reduction in survival after 5 and 10 years, within this high-risk group PSA level was not associated with prostate cancer-specific mortality [8] . Gleason score and the presence of metastasis were the strongest predictors of prostate cancer-specific mortality in this group with high PSA at presentation [8] . What is clear is that patients classified as having low or intermediate risk prostate cancer (Gleason score \8 and PSA \20 ng/ml) may have a 10-year prostate cancer-specific mortality of \5% [9, 10] , and avoiding unnecessary treatment is a challenge in these patients [11, 12] . Patients with high-risk prostate cancer make up a considerable proportion of newly diagnosed patients and have much higher mortality rates, and therefore, the challenge in these men is to increase overall survival while reducing any adverse effects of treatment. However, this high-risk population is heterogeneous and more information is needed on the validity of suggested prognostic indicators, such as the number and location of bone metastases, visceral metastases, Gleason score, and the initial PSA level [3, 13] .
This article reviews the current and ongoing role of androgen deprivation therapy (ADT) [3] .
Androgen deprivation can be achieved with a number of different types of ADT, including GnRH agonists, GnRH antagonists, and oestrogens. Anti-androgens are also sometimes used to inhibit the action of androgens. GnRH agonists, of which the most widely used include triptorelin, goserelin, and leuprolide, stimulate gonadotropins from the anterior pituitary gland and the production of testosterone in men, but continued administration leads to the downregulation of pituitary GnRH receptors, which quickly results in the suppression of gonadotropins [luteinising hormone (LH) and follicle stimulating hormone (FSH)] followed by a decrease in testosterone levels [14, 15] . GnRH antagonists (e.g., degarelix) competitively bind to the pituitary GnRH receptors and directly inhibit the release of gonadotropins and lead to reduced testosterone levels [16] . Oestrogens induce pituitary suppression of gonadotropin secretion and inhibit the production of androgens in the testicles but are rarely used due to their side effect profile [17] .
Anti-androgens, which bind to androgen receptors and thereby block the effect of endogenous androgens, are used in combination with GnRH agonists to achieve complete androgen blockade (CAB) [18] . In the short term, the concomitant use of anti-androgens prevents the flare-up that can occur when initiating GnRH agonist therapy [18] . Anti-androgens include bicalutamide, flutamide, and the more recently developed enzalutamide [19] . Moreover, abiraterone is a novel androgen synthesis inhibitor that has been shown to block androgen synthesis in adrenal glands and prostate cancer cells. Both abiraterone and enzalutamide are generally indicated for second-line treatment when castration resistance develops with ADT [20] [21] [22] .
While ADT is effective for reducing testosterone and PSA levels, almost all men treated in the long term develop castrate-resistant prostate cancer (CRPC) [23, 24] , with more than 80% exhibiting bone metastases upon diagnosis of CRPC.
TRIPTORELIN AS ADT
The most widely used ADT in clinical practice is Triptocare study in 326 adult men with locally advanced or metastatic prostate cancer who were naïve to ADT [42] (Fig. 2) . Castration is also maintained in the longer term [43] . The Triptocare LT study (ClinicalTrials.gov identifier, NCT01383863) showed that castrate levels of testosterone were maintained 3 years after starting ADT in men recruited into the Triptocare study; however, regular measurement of testosterone levels was infrequent in routine clinical practice [44] .
In general, similar results have been reported internationally in ethnically different populations [15, 45, 46] .
In addition to the standard castrate testosterone threshold of \50 ng/dl, the 1-, 3-, and 6-month formulations of triptorelin have been shown to achieve the most stringent definition of castration (i.e., serum testosterone \20 ng/dl) in [90% of patients at 6, 9, and 12 months post-IM injection [28, 47] .
Although this more stringent definition of castration has not been widely adopted, the EAU guidelines state that a \20 ng/dl cut-off would be more appropriate, as better results are observed with lower levels of testosterone compared to 50 ng/dl [3] . It is, therefore, important to demonstrate in clinical trials that a high proportion of patients achieves this lower level with ADT. The sustained suppression of testosterone with these triptorelin formulations leads to reductions in PSA levels. The triptorelin 3.75 mg 1-month formulation was shown to reduce median PSA levels from 46.8 ng/ml at baseline to 1.3 ng/ml at 9 months in 140 men with advanced prostate cancer [40] . Likewise, triptorelin 11.25 mg 3-month formulations reduced serum PSA level in treated patients [39, 45] . In one of these studies, 41 patients with newly diagnosed locally advanced or metastatic prostate cancer were administered a showed reductions in median PSA from 112.7 ng/ml at baseline to 10.4 and 11.6 ng/ml at 3 and 6 months, respectively [45] . Substantial PSA decreases were also observed with the triptorelin 22.5 mg 6-month formulation from 84 days post-injection [15, 42] (Fig. 2) . The longer term Triptocare LT study, which included 180 patients who had participated in and received triptorelin treatment in the Triptocare study, showed that median serum PSA reductions were maintained after 3 years of ADT [44] . The median time to PSA nadir was 185 days [44] .
All of the aforementioned efficacy data were reported with the IM administration of triptorelin. Recently, SC administration of triptorelin pamoate 11.25 mg 3-month formulation was shown to achieve castrate levels of testosterone within 4 weeks of the Fig. 2 Change in testosterone (a) and serum PSA (b) levels from baseline with sustained-release 22.5 mg 6-month triptorelin in men with advanced prostate cancer [42] . 
Effect on Symptoms
Up to 40% of men with localized prostate cancer may have moderate or severe lower urinary tract symptoms (LUTS) [48] , but data on the impact of ADT on LUTS are limited [49] [50] [51] . Recently, the preliminary results of an observational study in six countries suggested that treatment with triptorelin 1-and 3-month formulations improved LUTS after 6 and 12 months, as measured by a significant reduction in the International Prostate Symptom Score (IPSS) [52] . Interestingly, the improvement in LUTS after triptorelin therapy, correlated with reductions in PSA levels [52] . Similar results were observed in a prospective observational study that included 325 Belgian patients with locally advanced or metastatic prostate cancer, the majority of whom (62%) [40, 41, 45] , but further study on bone pain relief is needed.
Tolerability
Across clinical trials of patients with advanced prostate cancer, sustained-release triptorelin 1-, 3-and 6-month formulations were generally well tolerated, and the safety profile is consistent between the sustained-release formulations [15, 28, 31, 40, 42, 54] . The most frequently occurring treatment-related adverse events (AEs) with both IM and SC administrations of triptorelin were characteristic of those observed following any GnRH agonist treatment and are due to the expected pharmacological effect of the drug, i.e., castration [15, 31] . Such AEs with IM administration included hot flushes (50% of patients), erectile dysfunction (4%), and decreased libido (3%) [26, 27] . Similarly, hot flushes (10.3%) were the most frequently reported AE with the SC administration of triptorelin followed by increased weight (5.6%)
[31].
Despite these AEs, discontinuation rates while receiving triptorelin are infrequent. For example, the IM administered triptorelin 22.5 mg 6-month formulation led to no withdrawals due to AEs in the pivotal trial of this formulation [15] . Equally, triptorelin 11.25 mg 3-month treatment did not lead to discontinuations due to AEs when administered by SC injection to patients with locally advanced or metastatic prostate cancer [31] .
Triptorelin in Routine Clinical Practice
Reports of triptorelin efficacy in clinical trials translate to real-world studies. For example, in a grouped analysis of 1241 men from six countries, mean PSA levels were 117.9 ng/ml before the men initiated triptorelin therapy and this was reduced to 8.5 and 16.6 ng/ml after 6 and 12 months treatment, respectively [52] . A recent preliminary report from the UK indicated that PSA remained suppressed when patients switched from any 3-month formulation of GnRH agonist to the triptorelin 22.5 mg 6-month formulation, and this switch may help reduce hospital resource use [55] . Studies of sustained-release formulations of triptorelin during routine clinical practice also demonstrate improvements in some aspects of health-related quality of life (HRQoL) and satisfaction in patients [52, 53, [55] [56] [57] [58] . In an observational study of everyday practice in France, 1438 patients initiating treatment with triptorelin 3-or 6-month formulations for prostate cancer were evaluated for reasons for prescription and patient preference. Most patients initiated the 6-month formulation (62.8% vs 37.2% for the 3-month formulation), primarily for physician-reported reasons relating to the simplification of the treatment regimen and fewer unnecessary visits. Most patients (*80%) were satisfied with their prescribed formulation [57] . A second French longitudinal, prospective study of elderly men aged 75 years or older with prostate cancer observed that 3-6 months of triptorelin treatment did not adversely influence HRQoL.
Notably, triptorelin treatment improved
HRQoL related to urinary symptoms and incontinence [56] .
One notable observation in many studies in routine practice is the low frequency of testosterone measurement-for example, in the Triptocare LT study, less than 20% of patients had testosterone levels measured at all time points [44] . Since testosterone level remains the primary biochemical surrogate efficacy parameter of medical castration in prostate cancer, the low frequency of testosterone measurement in practice is a concern. Greater efforts should be made to ensure testosterone measurement in future observational studies and registries to improve the quality of outcomes data, and initiatives, such as the Prostate Cancer Outcomes Registry-Australia and New Zealand, may help in this respect [59] .
ARE ALL ADTS THE SAME? [61] . A mixed treatment comparison meta-analysis of a total of six studies of the selected agents revealed that leuprolide and goserelin were associated with increased mortality compared with degarelix (odds ratio [OR] 1.8 and 1.9, respectively). In contrast, mortality with triptorelin was lower than with degarelix (OR 0.5), leading the NICE Evidence Review Group to consider that the treatment effect of triptorelin on overall survival may differ from that of leuprolide and goserelin [61] . While this analysis is intriguing, more large-scale head-to-head comparisons would be needed to draw firm conclusions on the effects of different ADTs on survival. [70] . This study also showed an 8.5 month increase in median time to biochemical, symptomatic or radiographic progression with the addition of chemotherapy. In addition, the addition of chemotherapy to the first-line hormonal therapy for high-risk, locally advanced, metastatic or recurrent prostate cancer was shown to increase median overall survival by 10 months in the STAMPEDE trial (ClinicalTrials.gov identifier, NCT00268476) [71] . However, the incidence of Grade 3-5 AEs was considerably higher in the group receiving chemotherapy than in the group not receiving chemotherapy [71] . Thus, it seems the combination of ADT and chemotherapy should be initiated earlier in the treatment algorithm for high-risk disease. In patients who have already initiated ADT, it may be less clear if potential survival advantages exist by continuing ADT when chemotherapy is initiated, but it seems logical to follow expert guidance that advocates maintaining ADT when initiating chemotherapy for metastatic prostate cancer [62] .
THE ONGOING PLACE OF ADT IN PROSTATE CANCER MANAGEMENT
Irrespective of the above arguments in favor of maintaining backbone ADT, continuation of ADT, and maintenance of testosterone levels \50 ng/dl were stipulated as inclusion criteria for entry into all randomized controlled trials of newer agents (e.g., abiraterone and enzalutamide) [20, 21, 72, 73] , and therefore, there is no evidence to support stopping ADT when initiating these other agents. An important question that requires more data is whether certain sequences of these treatments or combinations of ADT and abiraterone and enzalutamide may benefit some patients.
Several studies have assessed the optimal sequencing of treatments in different patient groups [74] [75] [76] [77] , but firm guidance is not currently possible.
As well as these issues surrounding ADT, the use of adjuvant ADT after radical prostatectomy when nodal involvement is detected continues to have an important role [3] . Similarly, adjuvant or neo-adjuvant ADT plus radiotherapy is established as standard practice for locally advance prostate cancer, especially when disease is classified as high risk [3, [78] [79] [80] [81] . 
